Skip to main content
European Medicines Agency's logo Go to homepage

Main navigation

  • Medicines
    • Find medicine
    • Therapeutic areas: latest updates
    • Download medicine data
    • What we publish on medicines and when
    • Medicines under evaluation
    • National registers
  • Human regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
    • Medical devices
    • Herbal products
  • Veterinary regulatory
    • Overview
    • Research and development
    • Marketing authorisation
    • Post-authorisation
  • Committees
    • Overview
    • How the committees work
    • CHMP
    • CVMP
    • PRAC
    • COMP
    • HMPC
    • CAT
    • PDCO
    • Working parties and other groups
  • News & events
    • Overview
    • News
    • Events
    • What's new
    • Committee highlights
    • Publications
    • Press and social media
    • Open consultations
    • RSS feeds
  • Partners & networks
    • Overview
    • EU partners
    • International activities
    • Patients and consumers
    • Healthcare professionals
    • Pharmaceutical industry
    • Networks
    • Health technology assessment bodies
  • About us
    • Overview
    • What we do
    • Who we are
    • How we work
    • Fees
    • Support to SMEs
    • Annual reports and work programmes
    • History of EMA
    • Careers
    • Procurement
    • Glossaries
    • About this website
    • Data protection and privacy
    • Contacts
  1. Home
  2. Medicines
  3. Keytruda - opinion on variation to marketing authorisation

Keytruda - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation.

pembrolizumab
Post-authorisationHuman

Page contents

  • Opinion
  • Key facts
  • News on Keytruda
  • More information on Keytruda

Opinion

On 27 February 2025, the Committee for Medicinal Products for Human Use (CHMP), following a re-examination procedure, adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda. The marketing authorisation holder for this medicinal product is Merck Sharp & Dohme B.V.

The CHMP adopted a new indication as follows:

Malignant pleural mesothelioma (MPM)

Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.

For information, the full indications for Keytruda will be as follows:1

Melanoma

Keytruda as monotherapy is indicated for the treatment of adults and adolescents aged 12 years and older with advanced (unresectable or metastatic) melanoma.

Keytruda as monotherapy is indicated for the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, IIC or III melanoma and who have undergone complete resection (see section 5.1).

Non‑small cell lung carcinoma (NSCLC)

Keytruda, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non‑small cell lung carcinoma at high risk of recurrence in adults (for selection criteria, see section 5.1).

Keytruda as monotherapy is indicated for the adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum‑based chemotherapy (for selection criteria, see section 5.1).

Keytruda as monotherapy is indicated for the first‑line treatment of metastatic non‑small cell lung carcinoma in adults whose tumours express PD‑L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR or ALK positive tumour mutations.

Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non‑squamous non‑small cell lung carcinoma in adults whose tumours have no EGFR or ALK positive mutations.

Keytruda, in combination with carboplatin and either paclitaxel or nab‑paclitaxel, is indicated for the first‑line treatment of metastatic squamous non‑small cell lung carcinoma in adults.

Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic non‑small cell lung carcinoma in adults whose tumours express PD‑L1 with a ≥ 1% TPS and who have received at least one prior chemotherapy regimen. Patients with EGFR or ALK positive tumour mutations should also have received targeted therapy before receiving KEYTRUDA.

Malignant pleural mesothelioma (MPM)

Keytruda, in combination with pemetrexed and platinum chemotherapy, is indicated for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma.

Classical Hodgkin lymphoma (cHL)

Keytruda as monotherapy is indicated for the treatment of adult and paediatric patients aged 3 years and older with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant (ASCT) or following at least two prior therapies when ASCT is not a treatment option.

Urothelial carcinoma

Keytruda, in combination with enfortumab vedotin, is indicated for the first-line treatment of unresectable or metastatic urothelial carcinoma in adults.

Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum‑containing chemotherapy (see section 5.1).

Keytruda as monotherapy is indicated for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin‑containing chemotherapy and whose tumours express PD‑L1 with a combined positive score (CPS) ≥ 10 (see section 5.1).

Head and neck squamous cell carcinoma (HNSCC)

Keytruda, as monotherapy or in combination with platinum and 5‑fluorouracil (5‑FU) chemotherapy, is indicated for the first‑line treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 (see section 5.1).

Keytruda as monotherapy is indicated for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD‑L1 with a ≥ 50% TPS and progressing on or after platinum‑containing chemotherapy (see section 5.1).

Renal cell carcinoma (RCC)

Keytruda, in combination with axitinib, is indicated for the first‑line treatment of advanced renal cell carcinoma in adults (see section 5.1).

Keytruda, in combination with lenvatinib, is indicated for the first‑line treatment of advanced renal cell carcinoma in adults (see section 5.1).

Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions (for selection criteria, see section 5.1).

Microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) cancers

Colorectal cancer (CRC)

Keytruda as monotherapy is indicated for adults with MSI-H or dMMR colorectal cancer in the following settings:

  • first‑line treatment of metastatic colorectal cancer;
  • treatment of unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy.

    Non-colorectal cancers

Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with:

  • advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation;
  • unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy.

Oesophageal carcinoma

Keytruda, in combination with platinum and fluoropyrimidine‑based chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus in adults whose tumours express PD‑L1 with a CPS ≥ 10 (see section 5.1).

Triple‑negative breast cancer (TNBC)

Keytruda, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence (see section 5.1).

Keytruda, in combination with chemotherapy, is indicated for the treatment of locally recurrent unresectable or metastatic triple‑negative breast cancer in adults whose tumours express PD‑L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease (see section 5.1).

Endometrial carcinoma (EC)

Keytruda, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy.

Keytruda, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation.

Cervical cancer

Keytruda, in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy), is indicated for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer in adults who have not received prior definitive therapy.

Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1.

Gastric or gastro-oesophageal junction (GEJ) adenocarcinoma

Keytruda, in combination with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.

Keytruda, in combination with fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 1 (see section 5.1).

Biliary tract carcinoma (BTC)

Keytruda, in combination with gemcitabine and cisplatin, is indicated for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.


1 New text in bold

 

CHMP post-authorisation summary of positive opinion for Keytruda

AdoptedReference Number: EMA/60149/2025

English (EN) (198.4 KB - PDF)

First published: 28/02/2025
View

Key facts

Name of medicine
Keytruda
EMA product number
EMEA/H/C/003820
Active substance
Pembrolizumab
International non-proprietary name (INN) or common name
pembrolizumab
Therapeutic area (MeSH)
  • Melanoma
  • Hodgkin Disease
  • Carcinoma, Renal Cell
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Transitional Cell
  • Squamous Cell Carcinoma of Head and Neck
  • Urologic Neoplasms
  • Endometrial Neoplasms
Anatomical therapeutical chemical (ATC) code
L01FF02
Marketing authorisation holder
Merck Sharp & Dohme B.V.
Date of opinion
27/02/2025
Status
Positive

News on Keytruda

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025
28/02/2025
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 December 2024
13/12/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2024
15/11/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 September 2024
20/09/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2024
26/07/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 February 2024
23/02/2024
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2023
10/11/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2023
13/10/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 September 2023
15/09/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023
21/07/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022
20/05/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022
22/04/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 March 2022
25/03/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 December 2021
17/12/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 October 2021
15/10/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 13-16 September 2021
17/09/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021
29/01/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020
11/12/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-30 April 2020
30/04/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2020
31/01/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019
18/10/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2019
26/07/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 January 2019
01/02/2019
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2018
19/10/2018
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 July 2018
27/07/2018
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018
01/06/2018
EMA restricts use of Keytruda and Tecentriq in bladder cancer
01/06/2018
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 6-9 November 2017
10/11/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017
21/07/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 March 2017
24/03/2017
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 December 2016
16/12/2016
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016
24/06/2016
New treatment option recommended for patients with advanced melanoma
22/05/2015
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 18-21 May 2015
22/05/2015

More information on Keytruda

  • Keytruda
This page was last updated on 28/02/2025

Share this page

Back to top

Product emergency hotline

OUTSIDE WORKING HOURS

About us
What we do
Careers
Committees & working parties
Regulatory network
European experts
Languages
Frequently asked questions
Glossaries
About this website
Cookies
Website data protection notice
Data protection at EMA
Search tips
Access to documents
Contacts
Send a question
EMA Service Desk (system support)
Services and databases

European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Tel: +31 (0)88 781 6000

How to find us
Postal address and deliveries
Business hours and holidays

  • RSS Feed
  • Bluesky
  • YouTube
  • LinkedIn
© 1995 - 2025 European Medicines Agency
European Union agencies network
An agency of the European Union